<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813670</url>
  </required_header>
  <id_info>
    <org_study_id>XPF-001-101</org_study_id>
    <nct_id>NCT00813670</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers</brief_title>
  <official_title>Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XPF-001 and to Investigate the Effect of Food on the Pharmacokinetics of a Single Dose of XPF-001 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xenon Pharmaceuticals Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
      single and multiple doses of XPF-001 in healthy volunteers.

      The effect of food on the pharmacokinetics of XPF-001 will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECGs, Telemetry, Vital Signs, Physical Examinations, Laboratory Assessments and Adverse Events.</measure>
    <time_frame>up to 14 days post dose</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Human Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Single dose of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Single dose of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Single dose of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Single dose of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Single dose of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: Repeated doses of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Repeated doses of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Repeated doses of XPF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XPF-001</intervention_name>
    <description>Single oral dose, or 6 days of repeated oral doses.</description>
    <arm_group_label>Cohort 1: Single dose of XPF-001</arm_group_label>
    <arm_group_label>Cohort 2: Single dose of XPF-001</arm_group_label>
    <arm_group_label>Cohort 3: Single dose of XPF-001</arm_group_label>
    <arm_group_label>Cohort 4: Single dose of XPF-001</arm_group_label>
    <arm_group_label>Cohort 5: Single dose of XPF-001</arm_group_label>
    <arm_group_label>Cohort A: Repeated doses of XPF-001</arm_group_label>
    <arm_group_label>Cohort B: Repeated doses of XPF-001</arm_group_label>
    <arm_group_label>Cohort C: Repeated doses of XPF-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects (Females of non-childbearing potential) with normal or clinically
             insignificant laboratory results, ECGs and physical examinations.

        Exclusion Criteria:

          -  Subjects with a presence or history of any clinically significant disease.

          -  Subjects who have participated in and investigational drug trial within 60 days of
             admission.

          -  Subjects who have used tobacco or nictoine products in the 1 month prior to admission

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>September 10, 2009</last_update_submitted>
  <last_update_submitted_qc>September 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Paul Goldberg, Senior Director Clinical Biology and Target Discovery</name_title>
    <organization>Xenon</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

